Company Profile

BeiGene, Ltd. (NASDAQ: BGNE)
9:00 PM UTC, 12/20/24
Last: $176.50 Change: +1.78 %Change: +1.02% Volume: 368,466
Detailed Quote
Open: $ 176.29   Volume: 368,466
High: $ 179.25   Yield(%) 0.00
Low: $ 175.80   P/E Ratio (ttm): n/a
Dividend ($): n/a   Market Cap ($): 17.06B
EPS ($) -8.24   Shares Out: 97.62M
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): -10.20
% Price Change (last 13 weeks): -12.02
% Price Change (last 26 weeks): 12.33
% Price Change (last 52 weeks): -1.34
% Price Change (year to date): -3.13
Management Effectiveness
Return on Equity (%): -22.26
Return on Assets (%): -14.47
Return on Invested Capital (%): -40.81
Profitability
Gross Profit Margin (%): 81.13
Net Profit Margin (%): -35.86
Operating Profit Margin (%): -49.12
Price & Volume
50-day Moving Average: $201.59
200-day Moving Average: $178.25
Avg. Daily Vol. (last 50 days): 384,504
Avg. Daily Vol. (last 200 days): 280,746
52-wk high: $248.16
52-wk low: $126.97
Bid: $175.00
Ask: $205.00
Company Information
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
BeiGene, Ltd.
94 Solaris Avenue Camana Bay Grand Cayman
George Town GT KY1-1108

Phone: 1.345.949.4123
Fax: n/a
http://www.beigene.com
Per Share Data
Earnings (1year) ($): -8.24
Annual Dividend ($): 0.00
Current P/E Ratio (ttm): n/a
Book Value ($): 33.82
Cash Flow ($): -8.33
Valuation Ratios
Price/Earnings (x): n/a
Price/Sales (x): 7.66
Price/Book (x): 5.33
Price/Cash Flow (x): n/a
Financial Strength
Quick Ratio (x): 2.09
Current Ratio (x): 2.32
LT Debt/Equity (x): 6.22
Total Debt/Equity (x): 26.30



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2021 Wall Street Horizon, Inc.